gempicker Saturday, 03/31/18 11:20:52 AM Re: None Post # of 43187 Next few weeks I expect 10-k and AS raise as officially done. From there there will probably be a little dilution as debt is consolidated and some financing is probably necessary to move company forward. I expect this not to be death spiral dilution, in fact I believe the financiers will have incentive to see pps rise significantly.. Meanwhile a PR campaign logically should initiate. Tell us about manufacturing, U of Maryland success, GSA and government sales beginning; incremental revenues and retail rollout plans. Hopefully tell us about funding package to get phase 2 clinicals rolling for MS pediatric. Tell us if you plan to pursue government grants and funding that is coming available to fight opiods. These funds could be all that is needed to strengthen Nyloxin case as a significant tool to fight pain, etc.. Nobody is denying the product, nor the potential. We just need a methodical structured approach and watch market valuations quickly rise to 20,30,50 million as success is achieved. Whether there is 2,2.5, or 3 Billion shares out won’t matter much as the stock surpasses .01 and sales and clinical pipelines have momentum. Optimism will be high and 100 or 200 million valuations will seem and realistically be more achievable in the following year.. Everyone wins: the company, the financiers, shareholders and most importantly the people who desperately need real solutions to medical issues. Be methodical.. be patient.. be successful..